ANA-975

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C14H16N4O7S
Molecular Weight	384.364
Optical Activity	UNSPECIFIED
Defined Stereocenters	4 / 4
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(=O)O[C@@H]1[C@@H](CO)O[C@H]([C@@H]1OC(C)=O)N2C(=O)SC3=C2N=C(N)N=C3

InChI

InChIKey=ZWELIJXAKMASLK-UGKPPGOTSA-N

InChI=1S/C14H16N4O7S/c1-5(20)23-9-7(4-19)25-12(10(9)24-6(2)21)18-11-8(26-14(18)22)3-16-13(15)17-11/h3,7,9-10,12,19H,4H2,1-2H3,(H2,15,16,17)/t7-,9-,10-,12-/m1/s1

HIDE SMILES / InChI

Molecular Formula	C14H16N4O7S
Molecular Weight	384.364
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	4 / 4
E/Z Centers	0
Optical Activity	UNSPECIFIED

Approval Year

Substance Class	Chemical Created by `admin` on `Sat Dec 16 11:31:12 GMT 2023` Edited by `admin` on `Sat Dec 16 11:31:12 GMT 2023`
Record UNII	5UN5EF99CE
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ANA-975

Code

English

((2R,3R,4R,5R)-4-ACETOXY-5-(5-AMINO-2-OXO-THIAZOLO(4,5-D)PYRIMIDIN-3-YL)-2-(HYDROXYMETHYL)TETRAHYDROFURAN-3-YL) ACETATE

Systematic Name

English

ISOTORABINE

Common Name

English

AN 975

Code

English

THIAZOLO(4,5-D)PYRIMIDIN-2(3H)-ONE, 5-AMINO-3-(2,3-DI-O-ACETYL-.BETA.-D-RIBOFURANOSYL)-

Systematic Name

English

Code System Code Type Description

PUBCHEM

11234476

Created by admin on Sat Dec 16 11:31:12 GMT 2023 , Edited by admin on Sat Dec 16 11:31:12 GMT 2023

PRIMARY

CAS

847453-47-8

Created by admin on Sat Dec 16 11:31:12 GMT 2023 , Edited by admin on Sat Dec 16 11:31:12 GMT 2023

PRIMARY

FDA UNII

5UN5EF99CE

Created by admin on Sat Dec 16 11:31:12 GMT 2023 , Edited by admin on Sat Dec 16 11:31:12 GMT 2023

PRIMARY

Related Record Type Details


					5UN5EF99CE

ANA-975

ACTIVE MOIETY

Comments:

Class: Antiviral, Nucleoside; Mechanism of Action: Interferon alpha stimulant, Natural killer cell stimulant, Toll-like receptor 7 agonist; Highest Development Phases: Discontinued for Hepatitis B, Hepatitis C; Most Recent Events: 26 Jul 2007 Discontinued - Phase-I for Hepatitis C treatment in Europe (PO), 26 Jul 2007 Discontinued - Phase-I for Hepatitis C treatment in United Kingdom (PO), 26 Jul 2007 Discontinued - Preclinical for Hepatitis C treatment in USA (PO)


					5UN5EF99CE

ANA-975

ACTIVE MOIETY

Comments:

ANA975, a 5-amino-3-beta -D-ribofuranosyl-3H-thiazolo(4,5-d)pyrimidin-2-one derivative, was synthesized in the search of an oral prodrug of isatoribine, a small molecule toll-like receptor 7 (TLR-7) agonist. Several strategies were studied to enable the kilogram-scale synthesis of ANA975. Three general total syntheses are described. In the phase I clinical study of ANA975 against hepatitis C virus (HCV), conversion to isatoribine in plasma was rapid and effective, delivering levels of isatoribine that have been shown to be clinically relevant.


					5UN5EF99CE

ANA-975

ACTIVE MOIETY

Comments:

SAN DIEGO, July 26 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) today announced that it and Novartis have decided to discontinue the development of ANA975, a phase 1b compound for the treatment of hepatitis C virus (HCV) infection. The parties have determined that the results received to date from the ongoing 13 week toxicology study together with the results observed in the previous 13 week toxicology study do not support further clinical evaluation of chronic daily dosing of ANA975 in hepatitis C patients.